About this Research Topic
Checkpoint inhibitors are a novel type of treatment for solid tumors, but the strategy for using them is vastly different in different cases. It would be great to develop a possible strategy for the case of immune checkpoint inhibitor technology and its use. Recently, attention to immune engineering has raised some promises in cancer immunotherapy by modifying proteins or cells to fight against cancer. They are expected to be superior tools to foster a longer and better quality of life for cancer patients. An example of this advance is nano immunotherapy to deliver specific ICIs or CAR T cells to fight cancer.
This research topic aims to discuss novel cancer targets in the context of immunotherapy and nano-immunotherapy. One of the most common problems with cancer treatment is resistance to immune therapy, even in chemotherapy. We expect to see novel cancer research using emerging medical technologies, such as peptides, CAR T cells and ICIs, to respond to this obstacle. This research topic will discuss these challenges at length. We are at the initial stage of this research, so more investigation is needed into tumor immunology to identify novel targets and technologies to treat cancer. This is still a breakthrough in the cancer therapy world, as a recent noble prize was dedicated to James P Alison, who is an immunologist, to find novel ICIs against cancer.
We welcome the submission of manuscripts including, but not limited to, the following topics:
Development of cancer immunotherapy strategies to fight against cancer
Novel technologies to fight against cancer through nano immunotherapy
Investigation of novel drugs to help immune systems in the tumor microenvironment
Watch Dr. Webster's webinar about the Topic here: https://drive.google.com/file/d/1zkWnLHhA-YdvbvxxavFs2UT0zUwp6gFW/view
Keywords: Cancer immunotherapy, tumor immunology, immune cell engineering technology, nano immunotherapy, and cancer drug technology
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.